chlorprothixene 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
623 113-59-7

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • chlorprothixene
  • chlorprothixen
  • chlorprotixen
  • chlorprotixene
  • chlothixen
  • chorprothixene
  • chlorprothixene hydrochloride
  • chlorprothixene HCl
  • taractan
A thioxanthine with effects similar to the phenothiazine antipsychotics.
  • Molecular weight: 315.86
  • Formula: C18H18ClNS
  • CLOGP: 5.48
  • LIPINSKI: 1
  • HAC: 1
  • HDO: 0
  • TPSA: 3.24
  • ALOGS: -5.94
  • ROTB: 3
  • Status: OFM
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
0.30 g O
50 mg P

ADMET properties:

PropertyValueReference
BA (Bioavailability) 41 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 13.70 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 11.50 mL/min/kg Lombardo F, Berellini G, Obach RS
t_half (Half-life) 25.80 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
June 19, 1967 FDA ROCHE

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Neuroleptic malignant syndrome 80.04 44.94 24 1666 12032 63475300
Drug interaction 75.01 44.94 56 1634 229075 63258257
Intentional self-injury 73.14 44.94 27 1663 25660 63461672
Extrapyramidal disorder 69.37 44.94 22 1668 13262 63474070
Intentional overdose 62.21 44.94 33 1657 74119 63413213
Serotonin syndrome 59.67 44.94 24 1666 28658 63458674
Rhabdomyolysis 46.82 44.94 23 1667 43928 63443404

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Neuroleptic malignant syndrome 107.49 36.43 34 1032 17900 34937965
Ileus paralytic 74.26 36.43 20 1046 5977 34949888
Gastrointestinal necrosis 45.09 36.43 12 1054 3417 34952448
Toxicity to various agents 39.92 36.43 39 1027 200323 34755542
Tardive dyskinesia 38.87 36.43 12 1054 5778 34950087
Akathisia 38.83 36.43 13 1053 8096 34947769

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Neuroleptic malignant syndrome 184.69 32.89 58 2567 27501 79714262
Drug interaction 75.88 32.89 80 2545 415103 79326660
Extrapyramidal disorder 74.38 32.89 28 2597 22651 79719112
Toxicity to various agents 66.15 32.89 75 2550 421465 79320298
Ileus paralytic 63.30 32.89 20 2605 9600 79732163
Serotonin syndrome 58.87 32.89 29 2596 44998 79696765
Muscle rigidity 56.07 32.89 22 2603 19860 79721903
Restlessness 55.05 32.89 28 2597 46464 79695299
Intentional overdose 49.39 32.89 35 2590 105925 79635838
Rhabdomyolysis 43.34 32.89 32 2593 103099 79638664
Akathisia 42.11 32.89 16 2609 13243 79728520
Gastrointestinal necrosis 38.40 32.89 12 2613 5553 79736210
Suicidal ideation 37.37 32.89 26 2599 76314 79665449
Myoglobin blood increased 35.81 32.89 10 2615 3141 79738622
Intentional self-injury 33.98 32.89 18 2607 32401 79709362
Suicide attempt 33.19 32.89 25 2600 82907 79658856

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC N05AF03 NERVOUS SYSTEM
PSYCHOLEPTICS
ANTIPSYCHOTICS
Thioxanthene derivatives
CHEBI has role CHEBI:35717 hypnotics
CHEBI has role CHEBI:48561 dopaminergic antagonists
CHEBI has role CHEBI:48873 acetylcholine receptor antagonist
CHEBI has role CHEBI:50919 antiemetico
CHEBI has role CHEBI:65190 typical antipsychotic drugs
MeSH PA D014150 Antipsychotic Agents
MeSH PA D002491 Central Nervous System Agents
MeSH PA D002492 Central Nervous System Depressants
MeSH PA D015259 Dopamine Agents
MeSH PA D018492 Dopamine Antagonists
MeSH PA D018377 Neurotransmitter Agents
MeSH PA D011619 Psychotropic Drugs
MeSH PA D014149 Tranquilizing Agents
CHEBI has role CHEBI:176497 geroprotectors

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Schizophrenia indication 58214004 DOID:5419
Neuroleptic malignant syndrome contraindication 15244003 DOID:14464
Senile dementia contraindication 15662003
Agranulocytosis contraindication 17182001 DOID:12987
Shock contraindication 27942005
Parkinsonism contraindication 32798002
Disorder of cardiovascular system contraindication 49601007 DOID:1287
Epilepsy contraindication 84757009 DOID:1826
Leukopenia contraindication 84828003 DOID:615
Stupor contraindication 89458003
Tardive dyskinesia contraindication 102449007
Disease of blood AND/OR blood-forming organ contraindication 191124002 DOID:74
Alcohol withdrawal syndrome contraindication 191480000
Benign prostatic hyperplasia contraindication 266569009
Retention of urine contraindication 267064002
Neutropenic disorder contraindication 303011007 DOID:1227
Coma contraindication 371632003
Angle-closure glaucoma contraindication 392291006 DOID:13550
Breastfeeding (mother) contraindication 413712001
Carcinoma of female breast contraindication 447782002
Drug Induced CNS Depression contraindication




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 8.66 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
D(2) dopamine receptor GPCR ANTAGONIST Ki 8.53 CHEMBL CHEMBL
5-hydroxytryptamine receptor 2A GPCR Ki 9.37 PDSP
5-hydroxytryptamine receptor 6 GPCR Ki 8.52 CHEMBL
D(3) dopamine receptor GPCR ANTAGONIST Ki 8.34 CHEMBL
D(1B) dopamine receptor GPCR Ki 8.05 CHEMBL
Histamine H1 receptor GPCR Ki 8.43 CHEMBL
Muscarinic acetylcholine receptor M1 GPCR Ki 7.96 PDSP
Muscarinic acetylcholine receptor M2 GPCR Ki 7.55 PDSP
Muscarinic acetylcholine receptor M3 GPCR Ki 7.66 PDSP
Muscarinic acetylcholine receptor M4 GPCR Ki 7.75 PDSP
Muscarinic acetylcholine receptor M5 GPCR Ki 7.60 PDSP
D(4) dopamine receptor GPCR Ki 9.19 PDSP
ATP-binding cassette sub-family G member 2 Transporter IC50 4.38 CHEMBL
Solute carrier family 22 member 1 Transporter IC50 4.11 CHEMBL
D(1A) dopamine receptor GPCR Ki 7.74 CHEMBL
5-hydroxytryptamine receptor 7 GPCR Ki 8.25 CHEMBL
Histamine H1 receptor GPCR IC50 8.97 CHEMBL
Pleiotropic ABC efflux transporter of multiple drugs Transporter IC50 5.29 CHEMBL

External reference:

IDSource
4017788 VUID
N0000146149 NUI
D00790 KEGG_DRUG
2406 RXNORM
4017788 VANDF
C0008290 UMLSCUI
CHEBI:3651 CHEBI
CHEMBL908 ChEMBL_ID
DB01239 DRUGBANK_ID
D002749 MESH_DESCRIPTOR_UI
667467 PUBCHEM_CID
11976 IUPHAR_LIGAND_ID
886 INN_ID
6469-93-8 SECONDARY_CAS_RN
9S7OD60EWP UNII
001516 NDDF
005139 NDDF
387317000 SNOMEDCT_US
57002000 SNOMEDCT_US
88585004 SNOMEDCT_US
CHEMBL1256658 ChEMBL_ID

Pharmaceutical products:

None